The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint

The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint

Summary: Lecanemab, an anti-amyloid antibody with effects on biomarker and clinical endpoints in early Alzheimer's Disease (AD), was granted accelerated approval by the FDA in 2023 and regulatory review in Europe is ongoing. We estimate the population potentially eligible for treatment with lec...

Full description

Bibliographic Details
Main Authors: Linus Jönsson, Anders Wimo, Ron Handels, Gunilla Johansson, Mercè Boada, Sebastiaan Engelborghs, Lutz Frölich, Frank Jessen, Patrick Gavin Kehoe, Milica Kramberger, Alexandre de Mendonςa, Pierre Jean Ousset, Nikolaos Scarmeas, Pieter Jelle Visser, Gunhild Waldemar, Bengt Winblad
Format: Article
Language:English
Published: Elsevier 2023-06-01
Series:The Lancet Regional Health. Europe
Subjects:
Passive immunotherapy
Antibodies against amyloid b-peptide
Prodromal AD
Mild AD
Lecanemab
Pricing
Online Access:http://www.sciencedirect.com/science/article/pii/S2666776223000765

Internet

http://www.sciencedirect.com/science/article/pii/S2666776223000765

Similar Items